INSMED INC's ticker is INSM and the CUSIP is 457669307. A total of 223 filers reported holding INSMED INC in Q1 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,137,858 | +90.9% | 678,726 | +59.5% | 0.00% | +100.0% |
| Q2 2023 | $8,977,735 | -33.1% | 425,484 | -46.0% | 0.00% | 0.0% |
| Q1 2023 | $13,426,551 | -31.2% | 787,481 | -19.4% | 0.00% | -50.0% |
| Q4 2022 | $19,519,261 | +36.4% | 976,940 | +47.0% | 0.00% | 0.0% |
| Q3 2022 | $14,312,000 | -13.3% | 664,435 | -20.6% | 0.00% | 0.0% |
| Q2 2022 | $16,504,000 | -17.1% | 836,918 | -1.2% | 0.00% | -33.3% |
| Q1 2022 | $19,899,000 | +31.3% | 846,766 | +52.2% | 0.00% | +50.0% |
| Q4 2021 | $15,150,000 | -38.5% | 556,169 | -37.8% | 0.00% | -33.3% |
| Q3 2021 | $24,620,000 | +4.3% | 893,972 | +7.7% | 0.00% | 0.0% |
| Q2 2021 | $23,615,000 | +23.4% | 829,751 | +47.6% | 0.00% | 0.0% |
| Q1 2021 | $19,144,000 | -4.6% | 562,067 | -6.8% | 0.00% | 0.0% |
| Q4 2020 | $20,077,000 | +44.6% | 603,098 | +39.6% | 0.00% | 0.0% |
| Q3 2020 | $13,884,000 | -2.4% | 431,977 | -16.3% | 0.00% | 0.0% |
| Q2 2020 | $14,221,000 | +71.7% | 516,387 | -0.0% | 0.00% | +50.0% |
| Q1 2020 | $8,282,000 | -66.5% | 516,617 | -50.0% | 0.00% | -66.7% |
| Q4 2019 | $24,696,000 | +49.2% | 1,034,186 | +10.2% | 0.01% | +50.0% |
| Q3 2019 | $16,553,000 | +1.6% | 938,363 | +47.4% | 0.00% | 0.0% |
| Q2 2019 | $16,291,000 | -23.5% | 636,406 | -13.1% | 0.00% | -33.3% |
| Q1 2019 | $21,286,000 | +56.7% | 732,219 | -29.3% | 0.01% | +50.0% |
| Q4 2018 | $13,581,000 | +3.4% | 1,035,157 | +59.4% | 0.00% | +33.3% |
| Q3 2018 | $13,133,000 | -21.3% | 649,494 | -7.9% | 0.00% | -40.0% |
| Q2 2018 | $16,681,000 | +10.6% | 705,283 | +5.3% | 0.01% | +25.0% |
| Q1 2018 | $15,089,000 | +37.7% | 670,020 | +90.6% | 0.00% | +33.3% |
| Q4 2017 | $10,960,000 | +28.3% | 351,517 | +28.4% | 0.00% | 0.0% |
| Q3 2017 | $8,544,000 | +21.5% | 273,787 | -33.2% | 0.00% | +50.0% |
| Q2 2017 | $7,032,000 | -63.2% | 409,741 | -62.4% | 0.00% | -33.3% |
| Q1 2017 | $19,104,000 | +35.9% | 1,091,028 | +2.7% | 0.00% | +50.0% |
| Q4 2016 | $14,054,000 | +149.9% | 1,062,204 | +174.2% | 0.00% | 0.0% |
| Q3 2016 | $5,624,000 | +39.5% | 387,336 | -5.2% | 0.00% | +100.0% |
| Q2 2016 | $4,031,000 | -54.0% | 408,781 | -40.8% | 0.00% | -66.7% |
| Q1 2016 | $8,755,000 | -35.5% | 691,024 | -7.6% | 0.00% | -40.0% |
| Q4 2015 | $13,569,000 | -15.9% | 747,585 | -14.0% | 0.01% | -16.7% |
| Q3 2015 | $16,133,000 | -14.4% | 868,821 | +12.5% | 0.01% | -14.3% |
| Q2 2015 | $18,854,000 | +85.6% | 772,060 | +58.1% | 0.01% | +75.0% |
| Q1 2015 | $10,157,000 | +54.6% | 488,302 | +15.0% | 0.00% | +100.0% |
| Q4 2014 | $6,569,000 | +1343.7% | 424,631 | +1117.8% | 0.00% | – |
| Q3 2014 | $455,000 | -40.8% | 34,869 | -9.3% | 0.00% | – |
| Q2 2014 | $768,000 | -31.3% | 38,461 | -34.5% | 0.00% | – |
| Q1 2014 | $1,118,000 | +58.4% | 58,685 | +41.3% | 0.00% | – |
| Q4 2013 | $706,000 | +47.1% | 41,544 | +35.3% | 0.00% | – |
| Q3 2013 | $480,000 | -57.8% | 30,700 | -67.7% | 0.00% | -100.0% |
| Q2 2013 | $1,138,000 | – | 95,141 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Asymmetry Capital Management, L.P. | 250,584 | $4,420,000 | 9.48% |
| Palo Alto Investors LP | 7,239,649 | $127,707,000 | 8.51% |
| Foresite Capital Management IV, LLC | 1,429,518 | $25,217,000 | 8.15% |
| First Light Asset Management, LLC | 1,294,743 | $22,839,000 | 3.45% |
| Foresite Capital Management II, LLC | 915,016 | $16,141,000 | 3.41% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 356,600 | $6,287,000 | 2.90% |
| ACUTA CAPITAL PARTNERS, LLC | 220,000 | $3,881,000 | 2.80% |
| EMERALD ADVISERS, LLC | 984,987 | $17,375,000 | 0.81% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 911,936 | $16,087,000 | 0.71% |
| Rock Springs Capital Management LP | 890,000 | $15,700,000 | 0.63% |